Kineret® (anakinra) approved in the EU for the treatment of Still’s disease
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved an extension of the indication for Kineret (anakinra) to include the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), in all 28 European Union (EU) member states. Still’s disease is a rare systemic multi-organ disorder of auto-inflammatory nature that affects approximately 25,000[1]